Therapeutic Monoclonal Antibodies in Oncology

Hanahan D. , Weinberg R.A. The hallmarks of cancer. Cell 2000; 100: 57–70

Kohler G. , Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7

Reilly R. , Sandhu J. , Alvarez-Diez T.M. . Problems of delivery of monoclonal antibodies: pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995; 28: 126–42

Winter G. , Harris W.J. Humanized antibodies. Immunol Today 1993; 14: 243–6

Jones P.T. , Dear P.H. , Foote J. . Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522–5

Reff M.E. , Hariharan K. , Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002; 9: 152–66

McLaughlin P. , Grillo-Lopez J. , White C. . IDEC-C2B8 rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33

Davis T. , Grillo-Lopez J. , White C. . Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18: 3135–43

Marcus R. , Imrie K. , Belch A. . An international multi-centre, randomised open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma. Blood 2003; 102: Abstr 87

Coiffier B. , Lepage E. , Briere J. . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–42

Coiffier B. , Herbrecht R. , Tilly H. . GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with analysis according to co-morbidity factors. Proc Am Soc Clin Oncol 2003; 22: 596

Mounier N. , Briere J. , Gisselbrecht C. . Rituximab and CHOP (R-CHOP) overcomes bcl2-associated resistance to chemotherapy in elderly patients with diffuse large B cell lymphoma (DLBCL). Blood 2003; 101: 4279–84

Demidem A. , Lam T. , Alas S. . Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–86

Johnson T.A. , Press O.W. Synergistic cytotoxicity of iodine-131-anti-CD20 antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 2000; 85: 104–12

Rayzman V. , Scott A. Monoclonal antibodies for cancer therapy. Cancer Forum 2002; 26: 104–8

Byrd J. , Murphy T. , Howard R. . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small cell lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–64

O'Brien S. , Kantarjian H. , Thomas D. . Rituximab dose escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–70

Hainsworth J. , Litchy S. , Barton J. . Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small-cell lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746–51

Byrd J. , Petersen B. , Park K. . Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia patients: results from CALGB 9712. Blood 2001; 98: Abstr 772

Witzig T. , White C. , Wiseman G. . Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–803

Witzig T. , Flinn I. , Gordon L. . Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab refractory follicular NHL. J Clin Oncol 2002; 20: 3262–9

Witzig T. , Gordon L. , Cabanillas F. . Randomised control trial of Yttrium 90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–63

Kaminski M. , Zelenetz A. , Press O. . Pivotal study of iodine 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918–28

Kaminski M. , Estes J. , Regan D. . Front-line treatment of advanced B-cell low-grade lymphoma with radiolabelled anti-B1 antibody: initial experience. Proc Am Soc Clin Oncol 1997; 16: 15a

Dillman R. Radiolabelled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20: 3545–57

Kim E. , Khuri F. , Herbst R. Epidermal growth-factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13: 506–13

Porebska I. , Harlozinska A. , Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumor Biol 2000; 21: 105–15

Salomon D.S. , Brandt R. , Ciardiello F. , Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995; 19: 183–232

Saltz L. , Rubin M.S. , Hochster H.S. . Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001; 20: Abstr 3

Saltz L.B. , Meropol N.J. , Loehrer PJ Sr . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8

Cunningham D. , Humblet Y. , Sienas S. . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45

Robert F. , Esekiel M. , Spencer S. . Phase I study of anti-epidermal growth-factor receptor cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234–43

Abbruzzese J. , Rosenberg A. , Xiong Q. . Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20: 130a

Gatzemeier U. , Rosell R. , Ramlau R. . Cetuximab in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the firstline treatment of patients with epidermal growth-factor receptor expressing advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: Abstr 642

Saltz L. , Kies M. , Abbruzzese J. . The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22: 204

Berger M.S. , Locher G.W. , Saurer S. . Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238–43

Slamon D.J. , Godolphin W. , Jones L.A. . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12

Borg A. , Baldetorp B. , Fernö M. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6: 137–43

Stål O. , Carstensen J.M. , Wingren S. Relationship of DNA ploidy and S-phase fraction to survival after first recurrence of breast cancer. Acta Oncol 1994; 33: 423–9

Quénel N. , Wafflart J. , Bonichon F. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995; 35: 283–91

Slamon D.J. , Clark G.M. , Wong S.G. . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 385: 177–81

Slamon D.J. , Leyland-Jones B. , Shak S. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92

Osaba D. , Slamon D. , Burchmore M. . Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106–13

Seidman A. , Hudis C. , Pierri M. . Cardiac dysfunction in the trastuzumab clinical-trial experience. J Clin Oncol 2002; 20: 1215–21

Schneider J.W. , Chang A.Y. , Rocco T.P. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001; 28(suppl): 18–26

Pegram M.D. , Slamon D.J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26: 89–95

Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002; 9(suppl): 36–44

Hurwitz H. , Fehrenbacher L. , Cartwright T. . Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: Abstr 3646

Yang J.C. , Haworth L. , Sherry R.M. . A randomised trial of bevacizumab, an anti-vascular-endothelial growth-factor antibody for metastatic renal cancer. N Engl J Med 2003; 349: 427–34

Johnson D.H. , Fehrenbacher L. , Novotny W.F. . Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91

Miller K. , Rugo H. , Cobleigh M. . Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treated with anthracycline and a taxane. Breast Cancer Res Treat 2002; 76(suppl): Abstr 36

Griffin J. , Linch D. , Sabbath K. . A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984; 8: 521–34

Schedinberg D. , Lovett D. , Divgi C. . A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone-marrow targeting and internalisation of radionuclide. J Clin Oncol 1991; 9: 478–90

Sievers E. , Larson R. , Stadtmauer E. . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–54

Bross P.F. , Beitz J. , Chen G. . Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–6

Furman R.R. , Coleman M. , Leonard J.P. Epratuzumab in non-Hodgkin's lymphomas. Curr Treat Options Oncol 2004; 5: 283–8

Stockmeyer B. , Schiller M. , Repp R. . Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10—a humanized human leucocyte antigen DR antibody. Br J Haematol 2002; 118: 959–67

Lundin J. , Kimby E. , Bjorkholm M. . Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 768–73

Vallis K.A. , Reilly R.M. , Chen P. . A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun 2002; 23: 1155–64

Sridhar S.S. , Seymour L. , Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4: 397–406

Welt S. , Ritter G. , Williams C.J. . Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003; 9: 1347–53

Huland E. , Heinzer H. Renal cell carcinoma: novel treatments for advanced disease. Curr Opin Urol 2003; 13: 451–6

Markovic S.N. , Suman V.J. , Vukov A.M. . Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol 2002; 25: 308–12

Nanus D.M. , Milowsky M.I. , Kostakoglu L. . Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170: S84–9

Murray N. , Salgia R. , Fossella F.V. Targeted molecules in small cell lung cancer. Semin Oncol 2004; 31: 106–11

Posey J.A. , Ng T.C. , Yang B. . A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003; 9: 1323–32

Wong J.Y.C. , Chu D.Z. , Yamauchi D.M. . A phase I radioimmunotherapy trial evaluating 90-yttrium-labelled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000; 6: 3855–63

Boghaert E.R. , Sridharan L. , Armellino D.C. . Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewis y and eliminates Lewis y-positive human carcinoma cells and xenografts. Clin Cancer Res 2004; 10: 4538–49